Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:MDNA)

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting

GlobeNewswire 18 hours ago

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire April 10, 2024

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire April 9, 2024

Medicenna shares preclinical data on treatment targeting tumours

Jocelyn Aspa April 9, 2024

Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire April 9, 2024

Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 4, 2024

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

GlobeNewswire March 6, 2024

Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update

GlobeNewswire February 14, 2024

Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

GlobeNewswire February 13, 2024
View More News ››

Opinion & Analysis (TSX:MDNA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:MDNA)

Surprised and grateful that MDNA ran up over 2.00

again thanks a million .
Galaxym31 - 4 days ago

Bloom Burton Conference presentation April 16

MDNA still has 11 milestones and events to announce this year.  Stay tuned! https://wsw.com/webcast/bloomburton9/mdna/2718720
windymayor1 - 6 days ago

RE:RE:RE:RE:RE:RE:Abstract

If you want to see truly impressive, take a look at Oncolytics Biotech (ONCY/ONC.to)....they're about to begin recruiting patients...
Peladawn - 6 days ago

RE:RE:RE:RE:RE:Abstract

Impressive day on positive news!
windymayor1 - April 10, 2024

RE:RE:RE:RE:Abstract

Good luck to ya!
ENEMENEMYNEMO - April 9, 2024

RE:RE:RE:Abstract

4 PR , 3 SD not feeling it I think they had about 160 people in the GBM trial , if the SP  moves up I will unload .
Galaxym31 - April 9, 2024
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp is a Canadian company engaged in the acquisition, exploration, and development of natural ...
View More »